Epidermal changes associated with symptomatic resolution of dandruff: Biomarkers of scalp health

International Journal of Dermatology

Volumn 50, Issue 1, 2011, Pages 102-113

  Kerr, Kathy ^a   Darcy, Trevor ^a   Henry, James ^a   Mizoguchi, Haruko ^a   Schwartz, James R ^a   Morrall, Stephen ^a   Filloon, Thomas ^a   Wimalasena, Rohan ^a   Fadayel, Gina ^a   Mills, Kevin J ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; INVOLUCRIN; KERATIN; PYRITHIONE ZINC; SKIN LIPID;

ADHERENT SCALP FLAKE SCORE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CORRELATION ANALYSIS; DANDRUFF; DOUBLE BLIND PROCEDURE; EPIDERMIS; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN BIOPSY; SKIN SURFACE; STRATUM CORNEUM;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; DERMATITIS, SEBORRHEIC; EPIDERMIS; FEMALE; HAIR PREPARATIONS; HUMANS; INFLAMMATION; INTERLEUKINS; KERATINS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PYRIDINES; SCALP; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650564382     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04629.x     Document Type: Article

References (25)

1. Warner RR, Schwartz JR, Boissy Y, et al. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol 2001; 45: 897-903.
2. Ashbee HR, Evans EGV. Immunology of diseases associated with Malassezia species. Clin Microbio Rev 2002; 15: 21-57.
3. Bulmer AC, Bulmer GS. The antifungal action of dandruff shampoos. Mycopathologia 1999; 9: 63-65.
4. Reygagne P, Poncet M, Sidou F, et al. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis 2007; 79: 397-403.
5. Pierard-Franchimont C, Pierard GE, Vroome V, et al. Comparative anti-dandruff efficacy between a tar and non-tar shampoo. Dermatology 2000; 200: 181-184.
6. Harding CR, Moore AE, Rogers JS, et al. Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function. Arch Dermatol Res 2002; 294: 221-230.
7. Rogers JS, Moore AE, Meldrum H, et al. Increased scalp lipids in response to antidandruff treatment containing zinc pyrithione. Arch Dermatol Res 2003; 295: 127-129.
8. Mills K, Suszcynsky-Meister E, Kincaid E, et al. Ceramide insufficiency in dandruff/seborrheic dermatitis is reversed by potentiated micronized platelet pyrithione zinc shampoo treatment. J Am Acad Dermatol 2008; 58(2 Suppl): AB41.
9. Kligman AM, McGinley KJ, Leyden JJ. The nature of dandruff. J Soc Cosmet Chem 1976; 27: 111-139.
10. Hay RJ, Graham-Brown RAC. Dandruff and seborrheic dermatitis: causes and management. Clin Exp Dermatol 1997; 22: 3-6.
11. Conti Diaz IA, Civila E, Veiga R. The importance of microscopic examination in the management of desquamative diseases of the scalp. Mycopathologia 2001; 153: 71-75.
12. Billhimer WL, Bryant PB, Murray KP, et al. Results of clinical trial comparing 1% pyrithione zinc and 2% ketoconazole shampoos. Cosmetic Dermatology 1996; 9: 34-39.
13. ® tape samples. Skin Res Technol 2007; 13: 330-342.
14. Robinson MK. Non-invasive clinical assessment of skin irritation/inflammation. In: Barel AO, Paye M, Maibach HI, eds. Handbook of Cosmetic Science and Technology, 3rd edn. New York, NY: Informa HealthCare USA, 2009; 481-488.
15. Kerr K, Mizoguchi H, Henry J, et al. Potentiated pyrithione zinc shampoo usage leads to pronounced alterations in scalp skin histology and biochemistry that underlie efficacy in dandruff/seborrheic dermatitis. J Am Acad Dermatol 2009; 60(1 Suppl): AB84.
16. Perkins MA, Cardin CW, Osterhues MA, et al. A non-invasive tape absorption method for recovery of inflammatory mediators to differentiate normal from compromised scalp conditions. Skin Res Technol 2002; 8: 187-193.
17. Skov L, Buerskens FJ, Zacharaie COC, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 2008; 181: 669-679.
18. Coulombe PA. Towards a molecular definition of keratinocyte activation after acute injury to stratified epithelia. Biochem Biophys Res Comm 1997; 236: 231-238.
19. Ekanayake-Mudiyanselage S, Aschauer H, Schmook FP, et al. Expression of epidermal keratins and the cornified envelope protein involucrin is influenced by permeability barrier disruption. J Invest Dermatol 1998; 111: 517-523.
20. Schmuth M, Yosipovitch G, Williams ML, et al. Pathogenesis of the permeability abnormality in epidermolytic hyperkeratosis. J Invest Dermatol 2001; 117: 837-847.
21. Jensen JM, Pfeiffer S, Akaki T, et al. Barrier function, epidermal differentiation, and human beta-defensin 2 expression in tinea corporis. J Invest Dermatol 2007; 127: 1720-1727.
22. Franssen MEJ, Boezeman JBM, van de Kerkhof PCM, et al. Monitoring hyperproliferative disorders in human skin: flow cytometry of changing cytokeratin expression. Cytometry B Clin Cytom 2004; 57: 32-39.
23. Nemes Z, Steinert PM. Bricks and mortar of the epidermal barrier. Exp Mol Med 1999; 31: 5-19.
24. Zeeuwen PL. Epidermal differentiation: the role of proteases and their inhibitors. Eur J Cell Biol 2004; 83: 761-773.
25. Yamane Y, Moriyama K, Yasuda C, et al. New horny layer marker proteins for evaluating skin condition in atopic dermatitis. Int Arch Allergy Immunol 2009; 150: 89-101.